These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16759004)

  • 1. [Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe].
    Li J; Peng XQ; Zhang J; Xu JP
    Yao Xue Xue Bao; 2006 Mar; 41(3):282-4. PubMed ID: 16759004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HPLC determination of five caffeine metabolites].
    Lu JF; Yi T; Cao XM; Zhuo HT; Lin SS
    Yao Xue Xue Bao; 1997 Aug; 32(8):607-11. PubMed ID: 11596311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2A6 phenotyping based on dietary caffeine intake in a Japanese population of non-smokers.
    Kimura M; Shimizu M; Kiyotani K; Nakagawa K; Kamataki T; Yamazaki H
    Drug Metab Lett; 2012 Jun; 6(2):67-72. PubMed ID: 22849705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers.
    Murayama N; Shimizu M; Kobayashi K; Kishimoto I; Yamazaki H
    Drug Metab Lett; 2017; 10(4):240-243. PubMed ID: 27842485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
    Bechtel YC; Haffen E; Lelouët H; Brientini MP; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2000 Oct; 38(10):467-75. PubMed ID: 11073287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk.
    Nowell S; Sweeney C; Hammons G; Kadlubar FF; Lang NP
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):377-83. PubMed ID: 11927498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2].
    Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM
    Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children.
    Sinués B; Fanlo A; Vicente J; Mayayo-Sinués E; Mayayo E; Labarta JI; Ferrandez-Longás A
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):45-9. PubMed ID: 17927692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
    Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
    Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
    Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM
    Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.
    Adehin A; Bolaji OO
    Drug Metab Pers Ther; 2015 Sep; 30(3):203-10. PubMed ID: 26098700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man.
    Chen Y; Kang Z; Yan J; Yang GP; Tan ZR; Zhou G; Ouyang DS
    J Ethnopharmacol; 2010 Oct; 132(1):213-8. PubMed ID: 20723593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.